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Summary 
Bacterial and retroviral superantigens (SAGs) stimulate a high proportion of T cells expressing 
specific variable regions of the T cell receptor (TCR) ~ chain. Although most alleles and isotypes 
bind SAGs, polymorphisms of major histocompatibility complex (MHC) class II molecules affect 
their presentation to T cells. This observation has raised the possibility that a TCR-MHC class 
II interaction can occur during this  recognition process.  To address  the importance of such 
interactions during SAG presentation, we have used a panel of murine T  cell hybridomas that 
respond to the bacterial SAG Staphylococcal enterotoxin B (SEB) and to the retroviral SAG Mtv-7 
when presented by antigen-presenting cells (APCs) expressing HLA-DK1. Amino acid substitutions 
of the putative TCR contact residues 59,  64,  66,  77,  and 81 on the DK1/$ chain showed that 
these amino acids are critical for recognition of the SAG SEB by T  ceils. TCK-MHC class II 
interactions are thus required for T  cell recognition of SAG. Moreover, Mtv-7 SAG recognition 
by the same T cell hybridomas was not affected by these mutations, suggesting that the topology 
of the TCK-MHC class II-SAG trimolecular complex could be different from one TCR to another 
and from one SAG to another. 
S 
uperantigens (SAGs) 1 stimulate a high proportion of T 
cells bearing specific V~ regions of the TCR (reviewed 
in 1). This activation requires APCs expressing MHC class 
II molecules (2-4). The SAG family includes retroviral prod- 
ucts of the mouse mammary tumor virus, and bacterial toxins 
produced mostly by Staphylococci  and Streptococci (reviewed 
in 1). Unlike conventional antigens (Ags), SAGs bind out- 
side of the polymorphic antigen binding groove of MHC 
class II molecules (5).  Site-directed mutagenesis has shown 
that Staphylococcal enterotoxin A (SEA) interacts with histi- 
dine 81 of the MHC class II ~ chain (6, 7) while amino acids 
36 and 39 of the DRot chain are critical for toxic shock syn- 
drome toxin 1 (8) and SEB binding (9, and our unpublished 
observations). 
Experiments suggested at first the absence of TCR-MHC 
class II contact during SAG recognition. This conclusion was 
inferred from the fact that most class II molecules can present 
SAGs to a given T cell (4, 10-12). Moreover, CD8 + T cells 
expressing TCKs restricted to MHC class I molecules recog- 
1 Abbreviations used in this paper: SAG, superantigen; SEA or B, Staphy- 
lococcal enterotoxin A or B. 
nize the MHC class II-SAG complex (13-15).  Finally,  the 
TCK can interact with SAGs in the absence of MHC class 
II positive cells although this interaction does not result in 
T  cell activation (16,  17). These results have led to the hy- 
pothesis that MHC class II molecules serve only as a scaffold 
for SAG presentation and are not directly in contact with 
the TCR.  A more systematic analysis  of SAG presentation 
suggests that TCK-MHC class II interactions are required 
for T cell stimulation by SAGs. Stimulation of T cell clones 
is affected by MHC class II polymorphisms (18-20)  and a 
skewing of TCR-Ot chain expression among T cells reactive 
to  retroviral  and  bacterial  SAGs was  reported  (21-23). 
Moreover, fine specificities of TCK for particular MHC class 
II-SAG complexes are influenced by the non-V/3 (D/3, J/3, 
Vot,  and Jot) elements of the TCR  suggesting that these 
regions might interact with MHC class II molecules (24, 25). 
The crystal structure of the bacterial toxin SEB supports this 
hypothesis since the TCK and MHC class II binding regions 
are adjacent thus permitting a direct contact between the three 
molecules (26). 
To address a possible role for an interaction between TCR 
and MHC class II during SAG recognition, we have used 
mutant MHC class II molecules at putative TCK contact 
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murine T cell hybridomas. These substitutions have allowed 
us to show that distinct TCR contact residues on MHC class 
II molecules affect the response of each hybridoma to SEB. 
These mutations do not affect Mtv-7 SAG presentation sug- 
gesting that the same T  cells interact in a different manner 
with the MHC class II molecules during SEB and Mtv-7 SAG 
recognition. These results provide a strong evidence for an 
interaction between the TCR and MHC class II molecules 
in the T  cell response to SAGs. 
Materials  and Methods 
Cell Lines.  Kmls 13.11, Kmls 12.6, and RG 17 are murine T 
cell hybridomas expressing the TCR V36 chain and are stimulated 
by SEB and Mtv-7 SAG (27, 28). 3DT52.5.8  is a CD4 negative 
murine T cell hybridoma specific  for D e and expressing the TCR 
V/~I and VB8.1 genes (29). This T cell hybridoma recognizes SEA 
and SEB but not Mtv-7 SAG (30). KR3 is a CD4 + murine T cell 
hybridoma  that expresses the TCR VBS.1 chain and recognizes 
SEB and Mtv-7 SAG (31). DAP-3 is a MHC class II negative mu- 
fine fibroblastic  cell line (32). The hybridomas Kmls 13.11 and Kmls 
12.6 were grown in DMEM (GIBCO BRL, Gaithersburg, MD) 
supplemented with 5% FCS (GIBCO BRL), 4 mM dextrose (Sigma 
Chemical Co., St. Louis, MO), 2 mM r-glutamine (GIBCO BRL), 
essential and nonessential amino acids (GIBCO BRL), 1 mM so- 
dium pyruvate (GIBCO BRL), 10 #M/~-mercaptoethanol  (Sigma 
Chemical  Co.),  and  20  #g/ml  gentamycin  (GIBCO  BRL). 
3DT52.5.8, RG17, and KR3 were grown in RPMI 1640 (GIBCO 
BRL) supplemented with 5% FCS, 2 mM L-glutamine, 10 #M 
3-mercaptoethanol,  and 20/zg/ml gentamycin. DAP-3 cells were 
cultured in DMEM supplemented with 5% FCS, 2 mM r-gluta- 
mine, and 20/zg/ml gentamycin. 
Generation of Mutant HLA-DR Molecules.  The SmaI-BamHI 
cDNA fragment that encodes DR1 (DRBI*0101) 3  chains was 
cloned between the filled-in SalI site and the BamHI site of the 
eukaryotic expression vector RSV.3 (33, 34). The cDNA fragment 
that encodes the DRc~ chain was also subcloned in the RSV.3 ex- 
pression vector (35). Site-specific  mutagenesis of the DR3 chain 
cDNA was performed as previously described (7) using the PCR 
overlap extension technique (36). The full-length PCR fragments 
carrying the mutations  on the DR3 chain cDNA were digested 
with SacI and StuI. This 454-bp fragment was shuffled into the 
SacI- and StuI-digested wild-type DR1 cDNA cloned in the RSV.3 
eukaryotic expression vector. Generation of the DRol mutant 39, 
42, 46 has been described elsewhere (9). All of the mutants gener- 
ated by PCR were confirmed by nucleotide sequencing. 
DNA Transfections.  DNA transfections were performed using 
the calcium phosphate coprecipitation technique as previously de- 
scribed (7). Homogeneous populations of DAP-3 cells expressing 
comparable levels  of  MHC class II molecules were obtained by two 
rounds of aseptic cell sorting on a FACStar  |  Plus (Becton Dick- 
inson Immunocytometry Systems, San Jose, CA). Stable transfec- 
tions of Mtv-7 sag gene in DAP-3 fibroblasts expressing wild-type 
or mutated MHC class II molecules were performed as previously 
described (9). 
Cytofluorometric Analysis of DAP-3 Cells Transfected with HLA- 
DR Molecules.  Cells  were stained with either I.-243 or 50D6, a 
mouse anti-human MHC class II antibody that recognizes all DR 
alleles except DR7 and DRw53,  followed by goat anti-mouse 
(GAM)-FITC (GIBCO BRL). As negative control, the different 
transfectants were stained with the secondary antibody alone. MHC 
class II expression  was analyzed  by flow cytometry using a FACScan  | 
(Becton Dickinson  Immunocytometry Systems). 
Stimulation of Murine T Cell Hybridomas.  Stimulation of the 
different  T cell hybridomas  with recombinant SEB (rSEB; a generous 
gift ofJ. Kappler and P. Marrack, National Jewish Hospital, Denver, 
CO) was carried out as follows. 75  x  103 T cells/well were added 
to 2  x  104 DAP-3 fibroblasts expressing wild-type or mutated 
HLA-DR molecules. Different concentrations (0-1 #g/ml) of  bac- 
terial toxin SEB were added to the coculture in 96-well plates and 
incubated for 24 h at 37~  5% CO2. Triplicates were performed 
for each experimental condition. T cell stimulation was determined 
by IL-2 production.  IL-2 production  was assayed by the capacity 
of the culture supernatants  to support  the proliferation of the 
IL2-dependent cell line CTLL.2, as measured using the hexosa- 
minidase colorimetric assay (37). Presentation of Mtv-7 SAG by 
mutated  MHC class II  molecules was performed  as previously 
described (9). 
Toxin Binding Analysis.  20/zg of rSEB were iodinated using 
0.5 #g of iodogen (Pierce Chemical Co., Rockford, IL) coated to 
tubes and 250 #Ci of l~SI (Amersham Corp.,  Toronto, Canada). 
Free iodine was removed from the labeled toxin using Sephadex 
G-10 exclusion chromatography. The ability of  different HLA-DR 
mutants  to bind SEB was determined as follows: 106 DAP-3 cells 
expressing the wild-type or mutated HLA-DR molecules were in- 
cubated with  100 ng of 12sI-toxins in 200/~1 of binding  buffer 
(DMEM  +  2% FCS +  0.1% NAN3) for 4 h at 37~  Tubes were 
agitated every 15-20 min. Duplicates were performed for each con- 
dition.  After incubation,  the cells were pelleted through an oil 
cushion (84% silicone oil and 16% mineral oil); pellets were cut 
from  the  tube  and  were  then  counted on  a  gamma-counter. 
Nonspecific binding was determined in the presence of a 100-fold 
excess (10 #g) of cold toxin. 
Results 
Mutations of  Putative TCR Contact Residues on HLA-DRlfl 
Chain Affect rSEB Presentation to V~8.1  Murine  T  Cell Hy- 
bridomas.  To test the importance of TCR.-MHC class II in- 
teractions for the recognition of SAG by T cells, we have sub- 
stituted several of the putative TCR contact residues on the 
/3 chain of HLA-DR1 by alanines  (Table 1). These mutated 
class  II  molecules were  then used  to  stimulate  two SEB- 
responsive VB8.1 § T  cell hybridomas (Fig.  1). Stimulation 
of 3DT52.5.8 by rSEB was observed with all the APCs ex- 
pressing the different mutated MHC class II molecules. Trans- 
fected cells expressing the wild-type DR1 molecule stimu- 
lated IL-2 production by both V38.1 + T  cell hybridomas 
even at concentrations of SEB as low as 1 ng/ml, whereas 
untransfected fibroblasts did not present SEB. Efficient pre- 
sentation of rSEB by the MHC class II molecules mutated 
along the c~-helix of the fll domain (DR1 59.64, DR1 66.68, 
DR1 77.78, DR.1  81A,  and DR1 81Y)  was observed with 
differences in the dose-response curve for each mutant (Fig. 
1).  Most of the mutations involving these residues led to 
an effect on the dose-response curve for both V38.1 hybrid- 
omas tested, namely 3DT52.5.8 (Fig. 1, A  and B) and KR3 
(Fig.  1,  C  and D).  The only mutant  that  seemed not  to 
affect the presentation of rSEB involved the H81Y substitu- 
tion. Indeed, cells expressing DR1  81Y were as efficient as 
wild-type DR1 molecule in presenting rSEB.  In contrast, 
mutant  DRa39.42.46,  which fails to bind SEB, does not 
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Cell line  Mutation 
Mean fluorescence value 
L-243  50D6 
DAP-3 
Dlkl 
DR1  59.64  BE59>A, Q64>A 
DR1  66.68  /3D66>A, 68>A 
DR1  77.78  ~T77>A,  Y78>A 
DR1  81A  /3H81>A 
DR1  81Y  ~H81>Y 
DRot39.42.46  otK39>A, V42>A, E46>K 
5  4 
120  106 
57  36 
76  76 
93  75 
38  19 
127  N.D. 
5  88 
N.D., Not done. 
present the toxin to both hybridomas even at the highest con- 
centration tested (Fig.  1). These results thus indicate that the 
putative TCR contact residues/359,/364,/366,  B77, and/381 
are involved in the presentation ofrSEB to the V/38.1 T cells, 
3DT52.5.8  and KR3. 
Mutations of  Putative TCR Contact Residues on HLA-DRfl  l 
Chain Abolish Presentation of SEB to Vfl6 Murine T Cell Hy- 
bridomas.  The effect of these mutations was then assessed 
on  the  presentation  of rSEB  to  V/36 +  hybridomas,  Kmls 
13.11, Kmls 12.6, and RG 17. The latter will respond to rSEB 
only when presented by human MHC class II molecules (18). 
As also shown in Fig. 2 A, they require 10-fold higher levels 
of rSEB to produce detectable levels of IL-2 when compared 
with V/~8.1  hybridomas (Fig.  1).  A  significant  decrease of 
the T cell response to SEB was observed when class II mole- 
cules mutated at TCR residues 59 and 64 were used to present 
rSEB to Kmls 13.11 (Fig. 2 A); IL-2 production required a 
10ofold higher concentration of SEB when compared with 
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Figure 1.  Dose-response  curve of 3DT52.5.8 (.4 and B) and KR3 (C and D) to DAP-3 cells transfected with wild-type and mutant MHC class 
II molecules.  T cell hybridomas  were incubated  24 h at 37~  with DAP-3 cells expressing  wild-type or mutated MHC class II molecules  in the presence 
of 0-100/zg/ml of toxins. Each condition was done in triplicate. Stimulation  of the T cell hybridomas  is indicated  by ILo2 production and was determined 
by the ability of culture supernatants to support the proliferation of the IL-2-dependent  cell line CTLL.2. 
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Figure  2.  Dose-response curve of 
V/~6 + T cell hybridoma  to Kmls 13.11 
(A and B), Kmls 12.6 (C and D), and 
RG17 (E and F) to DAP-3 cells trans- 
fected  with wild-type  and mutant  DR1 
molecules.  The cocultures  and Ib2 mea- 
surements were performed  as described 
in Fig. 1. 
wild-type class II molecules. In contrast cells expressing mu- 
tants DR1 66.68 were as efficient in presenting rSEB as ceils 
expressing the wild-type DR1 molecule. Moreover, as shown 
in Fig. 2 B, mutation of residue B81 to either an alanine (DR1 
81A) or a tyrosine (DR1 81Y) complete abrogated presenta- 
tion of rSEB to Kmls 13.11 even though they express high 
and comparable levels of MHC class II molecules (Table 1). 
Mutation of the other putative TCR contact residues/~77 
(DK1 77.78)  (Fig.  2 B) had no effect on rSEB presentation 
to Kmls 13.11. These results indicate that TCtk residues/~59, 
/364, and ~81 are critical for SEB recognition by Kmls 13.11 
T  cells in the context of DR1. 
The effect of the same mutations was also determined for 
two other VB6 + murine T  cell hybridomas. Interestingly, 
presentation of rSEB to Kmls 12.6 involved different puta- 
tive TCR contact residues on MHC class II molecules than 
what was observed with Kmls 13.11. As illustrated in Fig. 
2 C  mutants B59.64  and ~66.68  had a moderate effect on 
SEB presentation in quantitative dose response  curve assays. 
Similar results were obtained for mutants 77.78  (Fig.  2 D). 
However mutation of residue ~81 to an alanine but not to 
a tyrosine abolished rSEB presentation to Kmls 12.6 (Fig. 
2 D). These results demonstrate the critical role of residue 
81 in the presentation of SEB to this TCR. They also sug- 
gest a role for aUelic polymorphism in the presentation of 
bacterial toxins to different TCRs since distinct amino acids 
at position 81 lead to different outcome, 
A distinct pattern was observed with the other V36 + T 
cell hybridoma R,G 17. Mutations at positions 59.64 and 66.68 
lead to drastic reduction of the capacity of these class II mol- 
ecules to present SEB (Fig. 2 E). Moreover the alanine sub- 
stitution at position 381 of DR1 affected the stimulation of 
RG 17 (Fig. 2/7). It is also interesting to note a significant 
enhancement in the stimulation of RG 17 by mutant DR1 
77.78. It is possible that presence of small side chains at these 
positions facilitates the interaction of the DR.1-SEB complex 
with the TCR. This effect was not observed with the other 
hybridomas. These results suggest that TCR-MHC class II 
interactions are required for efficient stimulation of T  cells 
with rSEB. Moreover,  the topology of the interaction be- 
tween the TCR and MHC class II molecules is different from 
one TCK to another since distinct TCR, residues affect the 
response  of each hybridoma. 
Mutation  of Putative  TCR  Contact Residues  on HLA-DRlfl 
Chain  Does  Not  Affect  SEB  Binding.  Quantitative binding 
assays were performed to verify if mutations of putative TCR 
contact residues on the ~ chain of DR1 affected the interac- 
tion with SEB. Fig. 3 shows that all the mutants efficiently 
bound  rSEB. The  variation  in  the  amount  of  12SI-rSEB 
binding was always correlated with the level of MHC class 
II expression on the different transfectants (Fig. 3). Specificity 
of the binding is shown using DAP-3 untransfected cells which 
do not bind 12SI-rSEB, Moreover, mutant DRa39.42.46 fails 
to bind lz~I-rSEB in this assay and had previously been shown 
to lose  the capacity to present SEB  to T  cells (9). 
Mutation of residue ~81 (either to an alanine or a tyro- 
sine) on HLA-DR.1 affects rSEB recognition by three out 
of five murine T  cell hybridomas. The results indicate that 
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Figure  3.  Binding ofrSEB on transfectants expressing wild-type or mu- 
tated HLA-DK molecules. Binding of 100 ng of 12SI-rSEB. Cells were in- 
cubated in the presence of radiolabeled toxins for 4 h at 37~  (white bars). 
Binding is expressed as bound cpm. The different transfectants were also 
stained with 1:243 and 50D6 mAbs to determine levels of MHC class II 
expression by flow cytometry.  M.F.V., mean fluorescence value. 
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Figure  4.  Mtv-7 SAG presentation  to different murine T cell hybrid- 
omas by HLA-DR1 mutated at putative TCR contact  residue fl81. Pre- 
sentation  of Mtv-7 SAG to KR3 + (VflS.l+), Kmls 13.11 (Vfl6+),  and 
Kmls 12.6 (Vfl6 +) T cells by DAP DR1 and DAP DR1 81A. Fibroblasts 
expressing wild-type or mutated HLA-DR1 molecules were transfected 
with the Mtv-7 sag gene and then used at different stimulator/effector ratios 
(1:1, 1:3, 1:10) to stimulate  the different murine T cell hybridomas.  The 
cocultures and II.-2 measurements  were performed as described in Fig. 1. 
Class II expression was monitored using the 50D6 antibody and the M.F.V. 
were:  DR.1, 178; DR1 Mtv-7,  120; DR1 81A Mtv-7,  140. 
SEB binding is not affected by these mutations.  DILl 81A 
or DILl 81Y bind rSEB proportionally to the levels of class 
II molecules expression at the cell surface (Fig. 3). Moreover, 
the binding of toxic shock syndrome type I is not impaired 
suggesting that these mutations do not alter the conforma- 
tion of HLA-DR1 (not shown). As expected, binding of SEA 
is completely abolished by mutation of residue 381 (not shown) 
thus confirming  our and others results  (6,  7). 
Mtv-7 SAG Presentation to Different Murine T  Cell Hybrid- 
omas by HLA-DRI Mutated at the Putative TCR Contact Res- 
idueflS1.  The requirement for TCR-MHC class II interac- 
tions in bacterial SAG recognition raised the possibility that 
it could also play a role in presentation  of endogenous retroviral 
SAG such as Mtv-7. Mutation of residue fl81 of HLA-DR1 
to an alanine  affects the rSEB response of the Vfl6 + hybrid- 
omas to rSEB.  To test a possible effect of this mutation on 
Mtv-7 SAG presentation, DILl and DR1 81A were transfected 
with the Mtv-7 Sag gene and used to stimulate the routine 
T cell hybridomas that e~ciently respond to Mtv-7 SAG. As 
shown in Fig.  4,  the two Vfl6 + hybridomas  (Kmls  13.11 
and Kmls  12.6)  responded as ef~ciently as the Vfl8.1 + hy- 
bridoma KR3 to Mtv-7 SAG presented by wild-type DR1 
or DR1 81A. Similar results were previously reported with 
another VB8 + hybridoma  stimulated with DILl  81A cells 
transfected transiently with Mtv-7 Sag (9).  This result is in 
sharp contrast to SEB presentation where Vfl8 + hybridomas 
responded well while Vfl6 + cells were not stimulated using 
class  II molecules DR1 81A (Figs.  1 and 2).  These resuhs 
suggest that  stimulation  of T  cells  with  retroviral  or bac- 
terial SAGs requires different TCIL-MHC class II interactions. 
A 3DT52.5.8  B Krnls 13.11 
KR3 
C Kmls 12.6  D  RG17 
Figure  5.  Position of the residues that have been substituted  on DRlfl 
chain.  The DRo~ chain is drawn in black and the DKfl chain in white. 
The MHC class II molecule drawing is adapted from the crystallographic 
structure  of HLA-DR1 described by Brown et al. (41). Mutated residues 
are indicated by circles. Small dots (.) represent residues that do not affect 
rSEB presentation.  Solid circles (0) represent residues that lead to a total 
abrogation  ofrSEB presentation;  ~tckedcircles  (@) represent residues that 
practically affect presentation  of rSEB; and empty circles (O) represent 
residues that  enhance  rSEB presentation. 
1925  Labrecque et al. Figure  6.  (A) Top view of the 
HLA-DRlc~I and/31 domain. The 
DRlc~I domain is on the top and 
the  DR1B1 domain  is  below. 
Residues shown in yellow are from 
the DRI~I domain and affect  T cell 
stimulation by SEB, but not SEB 
binding. (B) A model for ternary 
complex formation between DR1, 
SEB,  and  TCR  based on  the 
DRI:SEB crystal  structure analysis 
and  DR1/3 chain mutation  that 
affect T  cell stimulation but  not 
SEB, Dlklc~l/31 domains and pep- 
tide are shown  in blue. SEB is shown 
in red and DR1 residues that affect 
T  cell stimulation but  not  SEB 
binding  are  shown in  yellow.  A 
model of the Vot and V~ regions 
of the TCR, based on known im- 
munoglobulin structures, is shown 
in white.  The TCR model is posi- 
tioned based on mutational data for 
both S. aureus toxins and TCRs as 
described (40). The model is con- 
sistent with the occurrence of di- 
rect  interactions between DRI~ 
chain residues and TCR residues in 
SAG-mediated stimuiation  of  T 
cells. 
Discussion 
In this study, we have clearly demonstrated  that residues 
that  are  not involved in  the binding of bacterial  SAGs are 
important for the stimulation of T lymphocytes by these mol- 
ecules.  Different  murine  T  cell  hybridomas  that  respond 
efficiently to rSEB and Mtv-7 SAG when presented by HLA- 
DR1 were used. Our results indicate that histidine 81 is crit- 
ical for the formation of the trimolecular complex involving 
the TCR of the different VB6 + routine T  cell hybridomas 
since substitution of histidine/381  of DR1 to either a tyro- 
sine or an alanine completely abrogated or strongly reduced 
SEB presentation  to these T  cells.  This effect is not due to 
a decreased binding of this toxin on the mutated MHC class 
II molecules (Fig. 3).  The lack of serological differences be- 
1926  TCR-MHC Class II Interactions in Superantigen Recognition tween mutated and wild-type DR molecules using a panel 
of 13 DR-specific mAbs indicates that  these mutations did 
not  lead  to  gross  conformational  modifications  (data  not 
shown). The latter is supported by the fact that DR1 mole- 
cules having the mutation 381Y are still able to present anti- 
genic peptides to six of eight DRl-restricted T cell lines (6) 
and SAGs to the V38.1 hybridomas used in the present study. 
Interestingly,  substitution of residue 381 of HLA-DR1 to 
a tyrosine does not abolish the SEB response of Kmls 12.6 
and RG 17 although  alanine  substitution  strongly affected 
this response. It is possible that substitution of the histidine 
381 to an alanine,  which has  a very small side chain,  does 
not allow an interaction with this particular TCR but that 
substitution to a tyrosine, which also possesses an aromatic 
side chain,  permits a more efficient contact.  Although  the 
crystal structure of class II suggests that H81 might interact 
with peptide (38), our results clearly show that residue 381 
is involved in an interaction with the TCR (Fig. 5).  Indeed 
a recent report has demonstrated a critical role for this res- 
idue in presentation but not binding of class II-restricted pep- 
tides (39). It is however possible that unconventional inter- 
actions between TCR and MHC occur during presentation 
of bacterial toxins since SEB binds on the class  II o~ chain 
and thus obscures TCR contact residues on this side of the 
groove (40). With the knowledge that residue 381 is directly 
involved in the binding of SEA (6, 7), it is more than likely 
that in SEA recognition  the TCR will interact with other 
residues on MHC class  II molecules. 
The role of TCR-MHC class II interactions in the response 
to SAG was further  confirmed by the differential effect of 
366 on T  cell hybridomas. Mutation of this residue almost 
abolished the presentation ofrSEB to RG 17 and Kmls 13.11 
but had little effect on other T cells. Although this mutation 
was done in conjunction with the mutation of residue 368, 
which is pointing into  the antigen binding groove, we do 
believe that the effect observed is due to mutation of the puta- 
tive TCR contact residue 366 (Fig. 6). Mutations of the puta- 
tive TCR contact residues 359 and 364 affect the presenta- 
tion of rSEB to four out of five hybridomas used in these 
experiments.  These results suggest that different routine T 
cell hybridomas see the SAG-MHC class II complex in dis- 
tinct ways (Fig. 5). Moreover, our results indicate that a par- 
ticular TCR does not interact with all putative TCR contact 
residues located on the MHC class II molecules. In contrast 
to the negative effect of mutation 59, 64, 66, and 81A and 
81Y, substitution of 3T77A,  Y78A led to a significant en- 
hancement of RG17 response to SEB. This effect is more likely 
to be due to the mutation of residue 77 which is pointing 
out toward the TCR whereas the aromatic ring and lateral 
side chain of residue 378 is oriented toward the peptide binding 
groove (Fig.  6). 
Recently, Ehrich  et al.  (39) have reported that mutation 
of putative TCR contact residues on the a  and 3  chain of 
I-E  k affect SEA presentation to T cells. Interestingly, not all 
murine  T  cell hybridomas were affected by mutation  of a 
particular  TCR  contact  residue  confirming  our  results. 
Moreover, they showed that the same T  cell hybridoma in- 
teract with different TCR contact residues in Ag- and SAG- 
specific responses (39). Our results also showed that the same 
T cell hybridoma interact with different TCR contact residues 
for SEB and Mtv-7 SAG recognition. This different topology 
of interaction  could result  from  the  use of different  SAG 
binding sites on MHC class II molecules (9). The localiza- 
tion of the SAG on the MHC molecule will probably deter- 
mine the orientation  of the CDR4 loop and by the same 
way the overall topology of the TCR-class II. 
The  results  presented  here  favor  a  model  in  which 
TCR-MHC  class II-SAG interactions  occur. The fact that 
SAG presentation is not truly MHC restricted does not rule 
out a TCR-MHC class II interaction, since the putative TCR 
contact residues on MHC class II molecules are highly con- 
served throughout evolution (41, 42). 8 of 10 putative TCR 
contact residues of the class II/3 chain are conserved between 
wild mice, laboratory mice, and humans.  Interestingly,  the 
presence of an histidine at position 381 is conserved among 
all human and murine MHC class II alleles and isotypes with 
the  exception  of DRw53  and  I-A  ~.  Other  TCR  contact 
residues are also identical within a class II isotype as all HLA- 
DR alleles share the same TCR contact residues. Moreover, 
some of these amino  acids (5 out of 24) are conserved be- 
tween MHC class I and class II molecules, which could ex- 
plain the recognition by CD8 + T  cells of SAG-MHC class 
II complexes. Consistent with this view, CD4 § and CD8 § 
T  cells use the same pool of V regions to recognize MHC 
and Ags (43-46) further supporting the possibility that TCRs 
expressed by CD8 + T  cells can interact with MHC class II 
molecules. 
The importance of TCR-MHC class II interactions will 
probably be influenced by the affinity of the TCR for the 
SAG. Weak SAGs or TCRs with low af~nity for SAGs will 
probably show a pattern  of MHC restriction  that  will be 
influenced by putative TCR contact residue of the MHC class 
II molecule. Thus,  it is interesting  to note that  the V38.1 
hybridomas, which are less dramatically affected by the MHC 
mutation, respond to much lower concentration (10-30-fold) 
of SEB and are likely to have a higher affinity for the toxin 
than the V36 § T cells. The existence of a direct contact be- 
tween the TCR and MHC class II molecules in SAG recog- 
nition may have important  implications during the in vivo 
response to SAG. Bacterial and retroviral SAGs have been as- 
sociated with the pathogenesis of several diseases (1, 47-54). 
MHC dass II polymorphisms of TCR contact residues may 
have an important role to play in the susceptibility to SAG- 
related diseases and on the level of T cell expansion, deletion, 
and unresponsiveness  observed after SAG encounter. 
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